Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

SELARL PHARMACIE ULIVI/PRUVOST : revenue, balance sheet and financial ratios

SELARL PHARMACIE ULIVI/PRUVOST is a French company founded 2 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in SAINT-FOLQUIN (62370), this company of category PME shows in 2025 a net income positive of 102 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - SELARL PHARMACIE ULIVI/PRUVOST (SIREN 978487395)
Indicator 2025 2024
Revenue N/C N/C
Net income 101 737 € 1 115 €
EBITDA N/C N/C
Net margin N/C N/C

Revenue and income statement

In 2025, SELARL PHARMACIE ULIVI/PRUVOST generates positive net income of 102 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2024-2025: 1 k€ -> 102 k€.

Net income (2025) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

101 737 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 895%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 8%. Low autonomy: the company heavily depends on external financing (banks, suppliers).

Debt ratio (2025) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

894.714%

Financial autonomy (2025) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

8.086%

Asset age ratio (2025) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

62.5%

Solvency indicators evolution
SELARL PHARMACIE ULIVI/PRUVOST

Sector positioning

Debt ratio
894.71 2025
2024
2025
Q1: 13.7
Med: 49.79
Q3: 129.09
Watch

In 2025, the debt ratio of SELARL PHARMACIE ULIVI/PR... (894.71) ranks in the top 25% of the sector. This ratio measures the weight of debt relative to equity. A high ratio may indicate excessive dependence on external financing.

Financial autonomy
8.09% 2025
2024
2025
Q1: 33.42%
Med: 53.72%
Q3: 72.08%
Watch

In 2025, the financial autonomy of SELARL PHARMACIE ULIVI/PR... (8.1%) ranks in the bottom 25% of the sector. This ratio represents the share of equity in total financing. Low autonomy may limit investment capacity and increase vulnerability.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 163.47. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2025) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

163.47

Liquidity indicators evolution
SELARL PHARMACIE ULIVI/PRUVOST

Sector positioning

Liquidity ratio
163.47 2025
2024
2025
Q1: 131.03
Med: 182.25
Q3: 258.64
Average -9 pts over 2 years

In 2025, the liquidity ratio of SELARL PHARMACIE ULIVI/PR... (163.47) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.

Positioning of SELARL PHARMACIE ULIVI/PRUVOST in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 277 transactions of similar company sales in 2025, the value of SELARL PHARMACIE ULIVI/PRUVOST is estimated at 1 616 104 € (range 1 096 696€ - 2 535 890€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2025
277 transactions
1096k€ 1616k€ 2535k€
1 616 104 € Range: 1 096 696€ - 2 535 890€
NAF 5 année 2025

Valuation method used

Net Income Multiple
101 737 € × 15.9x = 1 616 104 €
Range: 1 096 696€ - 2 535 890€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare SELARL PHARMACIE ULIVI/PRUVOST with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de détail de produits pharmaceutiques en magasin spécialisé

Frequently asked questions about SELARL PHARMACIE ULIVI/PRUVOST

What is the revenue of SELARL PHARMACIE ULIVI/PRUVOST ?

The revenue of SELARL PHARMACIE ULIVI/PRUVOST is not publicly disclosed (confidential accounts filed with INPI).

Is SELARL PHARMACIE ULIVI/PRUVOST profitable?

Yes, SELARL PHARMACIE ULIVI/PRUVOST generated a net profit of 102 k€ in 2025.

Where is the headquarters of SELARL PHARMACIE ULIVI/PRUVOST ?

The headquarters of SELARL PHARMACIE ULIVI/PRUVOST is located in SAINT-FOLQUIN (62370), in the department Pas-de-Calais.

Where to find the tax return of SELARL PHARMACIE ULIVI/PRUVOST ?

The tax return of SELARL PHARMACIE ULIVI/PRUVOST is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SELARL PHARMACIE ULIVI/PRUVOST operate?

SELARL PHARMACIE ULIVI/PRUVOST operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.